Nicotine polacrilex and Application site urticaria - a phase IV clinical study of FDA data

Summary:

Application site urticaria is reported only by a few people who take Nicotine Polacrilex.

The phase IV clinical study analyzes which people take Nicotine polacrilex and have Application site urticaria. It is created by eHealthMe based on reports of 5,484 people who have side effects while taking Nicotine polacrilex from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Nov, 30, 2022

5,484 people reported to have side effects when taking Nicotine polacrilex.
Among them, 2 people (0.04%) have Application site urticaria.


What is Nicotine polacrilex?

Nicotine polacrilex has active ingredients of nicotine polacrilex. It is often used in quit smoking. eHealthMe is studying from 5,509 Nicotine polacrilex users for its effectiveness, alternative drugs and more.

What is Application site urticaria?

Application site urticaria is found to be associated with 382 drugs and 279 conditions by eHealthMe.

Number of Nicotine polacrilex and Application site urticaria reports submitted per year:

Could Nicotine polacrilex cause Application site urticaria?

Gender of people who have Application site urticaria when taking Nicotine polacrilex *:

  • female: 50 %
  • male: 50 %

Age of people who have Application site urticaria when taking Nicotine polacrilex *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 100 %

Common drugs people take besides Nicotine polacrilex *:

  1. Nicoderm Cq: 1 person, 50.00%

Common side effects people have besides Application site urticaria *:

  1. Dermatitis Contact (skin reaction (dermatitis) resulting from exposure to allergens): 2 people, 100.00%
  2. Swallowing Difficulty: 1 person, 50.00%
  3. Nausea (feeling of having an urge to vomit): 1 person, 50.00%
  4. Indigestion: 1 person, 50.00%
  5. Hiccups (an involuntary spasm of the diaphragm and respiratory organs, with a sudden closure of the glottis and a sound like a cough): 1 person, 50.00%
  6. Application Site Erosion: 1 person, 50.00%

* Approximation only. Some reports may have incomplete information.

Do you take Nicotine polacrilex and have Application site urticaria?

Check whether Application site urticaria is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

How severe was Application site urticaria and when was it recovered:

Expand to all the drugs that have ingredients of nicotine polacrilex:

Alternative drugs to, pros and cons of Nicotine polacrilex:

Common Nicotine polacrilex side effects:

Browse all side effects of Nicotine polacrilex:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Application site urticaria treatments and more:

COVID vaccines that are related to Application site urticaria:

Common drugs associated with Application site urticaria:

All the drugs that are associated with Application site urticaria:

Common conditions associated with Application site urticaria:

All the conditions that are associated with Application site urticaria:

How the study uses the data?

The study uses data from the FDA. It is based on nicotine polacrilex (the active ingredients of Nicotine polacrilex) and Nicotine polacrilex (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: